Journal
CHEST
Volume 125, Issue 2, Pages 52S-61SPublisher
ELSEVIER SCIENCE BV
DOI: 10.1378/chest.125.2_suppl.52S
Keywords
anti-inflammatory activity; asthma; clarithromycin; COPD; erythromycin; macrolides; roxithromycin; sinusitis
Categories
Ask authors/readers for more resources
In addition to their well-known antimicrobial activity, macrolides possess inummomodulatory properties that may confer beneficial effects to patients with respiratory diseases associated with chronic inflammation. These properties include attenuation of inflammatory responses in the lung, mucoregulatory properties, and effects on bronchial responsiveness. Macrolides increase mucociliary clearance, improve sinusitis symptoms, and decrease nasal secretions and polyp size in patients with sinusitis. They also have been shown to modify the inflammatory response associated with chronic sinusitis. In patients with asthma, macrolides have been reported to reduce airway hyperresponsiveness and improve pulmonary function, and have historically been selected for their steroid-sparing effect. Preliminary data from studies of patients with COPD have shown improvements in symptom scores and FEV, after macrolide treatment. As biological response modifiers, macrolides have the potential to improve the outcomes of patients with inflammatory airway diseases. Large scale, placebo-controlled clinical trials designed to assess long-term efficacy and safety in these diseases are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available